It isn’t entirely clear why the efficacy ... least two years. Pfizer executives, meanwhile, pledged to increase their shot’s market share during a January investor call. Moderna has said ...

according to Pfizer. Administering a third dose restores protective efficacy back up to 95% or more, it said. Meanwhile, Moderna also reported new data with its mRNA-1273 jab – which won't be ...

Most experts had hoped for 70% efficacy or higher ... of the leading vaccines require two shots. Pfizer's doses are given three weeks apart, while Moderna and AstraZeneca's are administered ...

U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by cost-cutting efforts and ...

The company will compete in a market where GSK and Pfizer already have a presence. Earlier this month, Moderna released data ... to compare the safety and efficacy of its RSV shot with others ...

Moderna and Pfizer have both said that updated versions ... led to concerns that the current generation of shots may lack efficacy. It's encouraging, then, that Moderna's mRNA-1273.715 vaccine ...

While the two vaccines appear to have very similar safety and efficacy profiles, Moderna's vaccine has a significant practical advantage over Pfizer's, CNN reported. Pfizer's vaccine has to be kept at ...

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...

Pfizer has said it plans to seek U.S. authorization for a third shot later this month. Moderna President Stephen Hoge said in an interview that the 93% efficacy data covers through March of this year.

These are the Pfizer/BioNTech, Moderna, and AstraZeneca/Oxford drugs ... drugs are built on mRNA technology and offer similar efficacy, preventing severe COVID-19 in about 95% of cases each.

The stellar efficacy and safety profile of ... by other innovative vaccines (GSK's Shingrix, Pfizer's Prevnar) launched in recent years. Moderna's platform technology allows new genetic sequences ...